Temporal trend analysis of the HIV/AIDS burden before and after the implementation of antiretroviral therapy at the population level from 1990 to 2020 in Ghana.
AIDS
Antiretroviral therapy
Ghana
HIV
Incidence
Mortality
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
20 07 2023
20 07 2023
Historique:
received:
24
12
2022
accepted:
17
07
2023
medline:
24
7
2023
pubmed:
21
7
2023
entrez:
20
7
2023
Statut:
epublish
Résumé
Antiretroviral therapy (ART) has helped reduce the burden of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) in the majority of countries. Its contribution to the HIV/AIDS burden in Ghana is still understudied. This study examined HIV/AIDS trends in Ghana before (1990-2004) and after (2004-2020) the implementation and expansion of ART. We obtained HIV/AIDS epidemiology and treatment data for the years 1990-2020 from the United Nations Programme on HIV/AIDS. We investigated the impact of the ART rollout on HIV/AIDS in Ghana using Joinpoint regression models. The HIV incidence, prevalence, and AIDS-related deaths decreased significantly after 2004, as ART coverage increased from 1% to 2004 to 60% in 2020. The HIV incidence decreased by approximately 3% (AAPC = -2.6%; 95% CI: -3.2, -1.9) per year from 1990 to 2004 and approximately 5% (AAPC = -4.5%; 95% CI: -4.9, -4.2) per year from 2004 to 2020. Between 1990 and 2004, the HIV prevalence increased by approximately 5% (AAPC = 4.7%; 95% CI: 3.6, 5.8) per year but decreased by 2% (AAPC = -1.9%; 95% CI: -2.1, -1.6) per year between 2004 and 2020. Between 1990 and 2004, the annual increase in AIDS-related mortality was 14% (AAPC = 13.8%; 95% CI: 12.6, 15.0), but between 2004 and 2020, it decreased at nearly a 4% (AAPC= -3.6%; 95% CI: -4.7, -2.5) annual rate. We found trends indicating progress in Ghana's fight against HIV/AIDS. However, the most significant declines occurred after the introduction of ART, suggesting that the scale-up of ART may have contributed to the decline in HIV/AIDS in Ghana. We advocate for the rapid expansion of ART in Ghana.
Sections du résumé
BACKGROUND
Antiretroviral therapy (ART) has helped reduce the burden of human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) in the majority of countries. Its contribution to the HIV/AIDS burden in Ghana is still understudied. This study examined HIV/AIDS trends in Ghana before (1990-2004) and after (2004-2020) the implementation and expansion of ART.
METHODS
We obtained HIV/AIDS epidemiology and treatment data for the years 1990-2020 from the United Nations Programme on HIV/AIDS. We investigated the impact of the ART rollout on HIV/AIDS in Ghana using Joinpoint regression models.
RESULTS
The HIV incidence, prevalence, and AIDS-related deaths decreased significantly after 2004, as ART coverage increased from 1% to 2004 to 60% in 2020. The HIV incidence decreased by approximately 3% (AAPC = -2.6%; 95% CI: -3.2, -1.9) per year from 1990 to 2004 and approximately 5% (AAPC = -4.5%; 95% CI: -4.9, -4.2) per year from 2004 to 2020. Between 1990 and 2004, the HIV prevalence increased by approximately 5% (AAPC = 4.7%; 95% CI: 3.6, 5.8) per year but decreased by 2% (AAPC = -1.9%; 95% CI: -2.1, -1.6) per year between 2004 and 2020. Between 1990 and 2004, the annual increase in AIDS-related mortality was 14% (AAPC = 13.8%; 95% CI: 12.6, 15.0), but between 2004 and 2020, it decreased at nearly a 4% (AAPC= -3.6%; 95% CI: -4.7, -2.5) annual rate.
CONCLUSIONS
We found trends indicating progress in Ghana's fight against HIV/AIDS. However, the most significant declines occurred after the introduction of ART, suggesting that the scale-up of ART may have contributed to the decline in HIV/AIDS in Ghana. We advocate for the rapid expansion of ART in Ghana.
Identifiants
pubmed: 37474958
doi: 10.1186/s12889-023-16321-3
pii: 10.1186/s12889-023-16321-3
pmc: PMC10360237
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1399Informations de copyright
© 2023. The Author(s).
Références
Int J Equity Health. 2012 Oct 16;11:62
pubmed: 23072340
Afr J AIDS Res. 2022 Mar;21(1):49-57
pubmed: 35361064
PLoS One. 2020 Mar 6;15(3):e0230159
pubmed: 32142549
AIDS Care. 2020 Aug;32(8):1036-1044
pubmed: 32362131
AIDS. 2013 Sep 10;27(14):2301-5
pubmed: 23669155
PLoS Med. 2012;9(7):e1001245
pubmed: 22802730
Drug Saf. 2016 Nov;39(11):1139-1149
pubmed: 27638659
JAMA. 2000 Jul 12;284(2):190-7
pubmed: 10889592
Afr J AIDS Res. 2020 Sep;19(3):222-230
pubmed: 32892711
Ann Intern Med. 2011 Aug 16;155(4):209-16
pubmed: 21768555
Pan Afr Med J. 2014 May 07;18:25
pubmed: 25368714
Patient Prefer Adherence. 2016 Mar 15;10:329-37
pubmed: 27042024
BMC Infect Dis. 2021 Aug 2;21(1):731
pubmed: 34340689
Bull World Health Organ. 2009 Oct;87(10):754-62
pubmed: 19876542
Lancet Infect Dis. 2011 Jul;11(7):516-24
pubmed: 21600849
N Engl J Med. 2016 Sep 1;375(9):830-9
pubmed: 27424812
SAGE Open Med. 2021 Jul 31;9:20503121211036142
pubmed: 34377475
BMC Womens Health. 2013 Jan 22;13:2
pubmed: 23336813
AIDS. 2019 Dec 1;33(15):2423-2430
pubmed: 31764107
Lancet Infect Dis. 2002 Aug;2(8):487-93
pubmed: 12150848
BMJ. 2011 Oct 11;343:d6016
pubmed: 21990260
BMC Womens Health. 2014 Oct 11;14:126
pubmed: 25306546
J Virus Erad. 2021 Jan 01;7(1):100027
pubmed: 33437495
BMC Geriatr. 2019 Nov 11;19(1):304
pubmed: 31711421
AIDS Care. 2016;28(6):684-8
pubmed: 26753839
Lancet Public Health. 2017 Jan;2(1):e35-e46
pubmed: 29249478
Gates Open Res. 2021 Jun 9;5:91
pubmed: 35355689
Glob Health Action. 2017;10(1):1331538
pubmed: 28621223
AIDS. 2010 Jan 2;24(1):123-37
pubmed: 19770621
PLoS One. 2013 Nov 13;8(11):e77981
pubmed: 24236010
AIDS. 2016 Jun 1;30(9):1475-9
pubmed: 26950317
ISRN AIDS. 2013 Dec 10;2013:873939
pubmed: 24386593